BioArctic AB (publ) (BIOA-B.ST)
BIOA-B.ST Stock Price Chart
Explore BioArctic AB (publ) interactive price chart. Choose custom timeframes to analyze BIOA-B.ST price movements and trends.
BIOA-B.ST Company Profile
Discover essential business fundamentals and corporate details for BioArctic AB (publ) (BIOA-B.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Oct 2017
Employees
107.00
Website
https://www.bioarctic.seCEO
Gunilla Osswald
Description
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
BIOA-B.ST Financial Timeline
Browse a chronological timeline of BioArctic AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 28 Aug 2025
EPS came in at kr 1.09 falling short of the estimated kr 1.26 by -13.49%, while revenue for the quarter reached kr 391.92M , beating expectations by +21.86%.
Earnings released on 21 May 2025
EPS came in at kr 11.53 surpassing the estimated kr 10.32 by +11.72%, while revenue for the quarter reached kr 1.29B , beating expectations by +303.00%.
Earnings released on 13 Feb 2025
EPS came in at -kr 0.36 surpassing the estimated -kr 0.57 by +36.84%, while revenue for the quarter reached kr 101.24M , missing expectations by -92.37%.
Earnings released on 14 Nov 2024
EPS came in at -kr 0.22 surpassing the estimated -kr 0.52 by +57.69%, while revenue for the quarter reached kr 76.63M , missing expectations by -32.88%.
Earnings released on 29 Aug 2024
EPS came in at -kr 0.77 matching the estimated -kr 0.77, while revenue for the quarter reached kr 49.84M , beating expectations by +5.74%.
Earnings released on 17 May 2024
EPS came in at -kr 0.65 surpassing the estimated -kr 0.75 by +13.33%, while revenue for the quarter reached kr 29.64M , missing expectations by -37.13%.
Earnings released on 14 Feb 2024
EPS came in at -kr 0.99 falling short of the estimated -kr 0.79 by -25.32%, while revenue for the quarter reached kr 11.02M , missing expectations by -3.30%.
Earnings released on 8 Nov 2023
EPS came in at kr 1.41 surpassing the estimated kr 0.93 by +51.61%, while revenue for the quarter reached kr 208.84M , beating expectations by +20.88%.
Earnings released on 12 Jul 2023
EPS came in at -kr 1.16 falling short of the estimated -kr 0.94 by -23.40%, while revenue for the quarter reached kr 2.71M , missing expectations by -96.24%.
Earnings released on 27 Apr 2023
EPS came in at kr 3.31 surpassing the estimated -kr 0.50 by +762.00%, while revenue for the quarter reached kr 393.43M .
Earnings released on 3 Feb 2023
EPS came in at -kr 0.66 surpassing the estimated -kr 0.82 by +19.51%, while revenue for the quarter reached kr 2.09M .
Earnings released on 20 Oct 2022
EPS came in at kr 1.54 falling short of the estimated kr 1.73 by -10.98%, while revenue for the quarter reached kr 218.23M .
Earnings released on 12 Jul 2022
EPS came in at -kr 0.52 falling short of the estimated -kr 0.01 by -5.10K%, while revenue for the quarter reached kr 4.24M .
Earnings released on 28 Apr 2022
EPS came in at -kr 0.50 surpassing the estimated -kr 0.53 by +5.66%, while revenue for the quarter reached kr 3.74M .
Earnings released on 3 Feb 2022
EPS came in at -kr 0.22 surpassing the estimated -kr 0.51 by +56.86%, while revenue for the quarter reached kr 4.71M .
Earnings released on 21 Oct 2021
EPS came in at -kr 0.43 matching the estimated -kr 0.43, while revenue for the quarter reached kr 3.95M .
Earnings released on 9 Jul 2021
EPS came in at -kr 0.39 surpassing the estimated -kr 0.46 by +15.22%, while revenue for the quarter reached kr 7.31M .
Earnings released on 21 Apr 2021
EPS came in at -kr 0.33 surpassing the estimated -kr 0.45 by +26.67%, while revenue for the quarter reached kr 7.18M .
Earnings released on 4 Feb 2021
EPS came in at -kr 0.15 surpassing the estimated -kr 0.43 by +65.12%, while revenue for the quarter reached kr 8.36M .
Earnings released on 14 Oct 2020
EPS came in at -kr 0.23 surpassing the estimated -kr 0.50 by +54.00%, while revenue for the quarter reached kr 10.55M .
BIOA-B.ST Stock Performance
Access detailed BIOA-B.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.